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standing. Internal validity was tested, assessing internal consistency, correlation
matrix using item/dimension correlation, factorial structure and differential item
functioning. External validation was performed versus motor symptoms, behav-
ioral symptoms, and the well-established QoL scale EuroQoL 5D. RESULTS: The
preliminary analysis supported the validity of the H-QoL-I. Face validity appeared
satisfactory (Missing data 7%); as for the original instrument, a ceiling effect was
observed for patients with severe HD. The H-QoL-I showed an acceptable reliability
(Cronbach’s alpha 0.85 for each dimension). The factor analysis explained 77% of
the total variance and split the items in 3 factors in the same way as the original
version. There was no differential item functioning neither between countries nor
gender. The Pearson’s correlation between the clinical motor score and the motor
functioning dimension was 0.89, between EQ-5D score and H-QoL-I total score, 0.71
and between the clinical depression/anxiety score and the psychological dimen-
sion of H-QoL-I, 0.63. CONCLUSIONS: Test–retest and sensitivity to change remain
to be performed, but current data support the validity of the H-QoL-I.
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OBJECTIVES: The H-CSRI is the first clinimetric patient assessed scale for patients
with Huntington’s disease (HD). It was originally developed and validated for
France and Italy. Such an instrument offers the advantage of allowing a remote
follow-up and getting information on the development of motor, functional and
behavioral disorders of HD patients perceived by the patient himself. The objective
of this study is to adapt and cross-culturally validate the H-CSRI for Germany,
Poland and USA. METHODS: The original questionnaire included three subscales
assessing the motor (13 Likert-type items in 4 dimensions), functional (7 Yes/No
questions) and behavioural ability (13 Likert-type items in 4 dimensions). The in-
strument was translated forwards and backwards by native speakers. It was then
reviewed and adjusted by local clinicians and tested for face validity. A total of 134
US, 60 Polish and 41 German HD patients filled in the H-CSRI questionnaire. Clas-
sical test theory and item response theory were used to assess its clinimetric prop-
erties.Cross-cultural validation was assessed by diferential item functioning
analysis. RESULTS: Among 235 patients, item response rates ranged from 86% to
93%. Face validity appeared satisfactory; as for the original instrument, there was a
floor effect on items related to psychotic disorder in the behavioral dimension. The
H-CSRI showed an acceptable reliability (Cronbach’s alphas 0.80). Factor analyses
demonstrated a satisfactory construct validity for the motor dimensions with 76%
of explained variance and for the behavioural dimensions with 74% of the ex-
plained variance. The differential item functioning analyses showed no item bias
between the three countries and between genders. CONCLUSIONS: These data
support the cross-cultural validity of the H-CSRI to assess the health status for
patients with Huntington’s disease and integrate the patient perspective for Ger-
many, Poland and US.
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OBJECTIVES: Ichthyoses form a group of ailments for which the main part of treat-
ment aims to reduce hyperkeratosis and to control sensory, articular and psycho-
logical complications. In infants, dermatologists do not restrict their treatment to
the cutaneous involvement, but endeavour to prevent the consequences of these
severe and obvious afflictions for the future of these patients. To explore the hand-
icap, in the largest sense, generated by ichthyosis using a questionnaire to express
the burden of the illness on the daily life of patients and their family, in order to
anticipate and treat it more effectively. METHODS: The questionnaire was devel-
oped following a strict methodological process involving a multidisciplinary team
incorporating various players (doctors, nurses, social workers) who are involved in
the treatment of patients and caring for their families in order to guarantee its
credibility and reliability. A review of the literature and discussions with the chil-
dren and their families were conducted in order to identify the concepts related to
the pathology. RESULTS: Exploratory assessments showed that the concept of
burden could be structured around five components: feeling of pain, daily life,
family and personal relationships, work and psychological impact. Ninety-six pre-
liminary items were identified at the end of the first discussion. A first analysis
managed to reduce these items to 40 whilst conserving the 5 components but
making it easier to use the analysis. The creation of a child module aimed at
children who are able to provide answers independently proved necessary.
CONCLUSIONS: Chronic pathologies such as ichthyosis, which remains a rare and
incapacitating illness, are difficult to assess by clinical or quality of life aspects alone as
their impact can be multidimensional. Family Burden Ichthyosis takes them all into
consideration in order to explain every angle of the handicap generated.
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OBJECTIVES: To develop a new instrument measuring neuropathic pain at and
below the level of spinal cord injury (SCI) based on pain intensity, pain interference
and pain descriptors. METHODS: An expert panel composed of pain specialists,
physiologists, rehabilitation doctors, neurologists, psychologists and methodolo-
gists was created to generate the items and to supervise the questionnaire con-
struction, following Classic Test Theory assumptions. A total of 12 Likert items, 2
multichoice items, 7 dichotomous indicators and 23 pain descriptors were pro-
posed. They were measured for at and below level pain in patients with traumatic
SCI between the C3 and T10 level. A subgroup of items was assessed for constant
pain, paroxysmal pain, and evoked pain. Item analysis, structural validity (explor-
atory factor analysis) and reliability (Cronbach’s alpha) were assessed. Correlation
with DN4, NPSI, BPI and MHI5 was studied for convergent validity. Cluster analysis
and multidimensional correspondence analysis were also used to study pain de-
scriptor behavior. RESULTS: A total of 153 patients recruited at 4 specialized hos-
pitals in Spain and Denmark. Women were 26%, and mean age 43 years (SD12.4).
Thirty five percent experienced below SCI level pain, 26% at level, and 39% both.
Factor analysis below SCI suggested that pain intensity and QoL interference were
related to constant non-evoked pain, while paroxysmal pain was related to night
disturbance and temperature-evoked pain. Scale reliability was 0.76 below and 0.80
at SCI level. Exploratory correlations with other standard diagnostic tools were
moderate. Descriptor clustering disclosed 5 main groups of pain types covering
most of the items used frequently in other instruments (DN4 or NPSI). Pain at and
below level differed in specific aspects. CONCLUSIONS: Initial psychometric prop-
erties of the EuroDolMed are good and support the use of this new instrument to
explore neuropathic pain in patients with SCI, although an effort should be made to
shorten it without losing precision.
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OBJECTIVES: To assess public preferences for the predictive genetic test for Alz-
heimer’s disease in the United States. METHODS: A rating conjoint analysis was
conducted using an anonymous online survey distributed by Qualtrics® to a gen-
eral population panel in April 2011 in the United States. The study design included
three attributes: Accuracy, Treatment Availability, and Anonymity. A total of 12
scenarios were used to elicit people’s preference by adopting an 11-point scale. The
respondents also stated their highest willingness-to-pay (WTP) for each scenario
by answering the open-ended questions. RESULTS: A total of 295 responses were
collected over four days. The results showed the most important attribute for the
aggregate model was Accuracy, contributing 64.73% to the preference rating. Treat-
ment Availability and Anonymity contributed 20.72% and 14.59% to the preference
rating, respectively. The most preferred scenario was the test with a 100% chance
of being correct, a cure for AD is available and the test result is anonymous. The
median WTP for the highest-rating scenario (Accuracy 100%, a cure is available,
test result is anonymous) was $100 (mean WTP was $276). The median WTP for the
lowest-rating scenario (Accuracy 40%, no cure but drugs for symptom relief, not
anonymous) was zero (mean WTP was $36). Four groups were identified using
cluster analysis revealing different patterns of importance among the three
attributes. CONCLUSIONS: The results of this study highlight the attributes con-
sumer find important when making the decision to obtain an AD genetic test.
These results should be of interests to policy makers, genetic test developers and
health care providers.
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OBJECTIVES: Previous research suggests that the Short Form 36 (SF-36) may cap-
ture some of the broad effects of MS that are not reflected in the Kurtzke Expanded
Disability Status Scale (EDSS) and may be appropriate when evaluating overall
health-related quality of life (HRQL). The purpose of this study was to explore the
relationship between an EDSS-correlated self-reported disability measure, the Pa-
tient Determined Disease Steps (PDDS), and SF-36 health domain scores.
METHODS: A convenience sample of US-residing participants with MS were re-
cruited through web-based patient advocacy organizations. Participants re-
sponded to questions pertaining to demographics, disease history, productivity,
urinary symptoms, and HRQL. Disability status was measured using the PDDS, an
8-point ordinal scale ranging from “Normal” to “Bedridden,” and general HRQL was
measured using the SF-36 version 2, a 36-item questionnaire comprised of 8 health
domain subscales and 2 summary scores normalized for direct comparison to the
US general population. Spearman rank correlation coefficients were calculated to
assess the relationship between SF-36 health domain scores and PDDS scores.
RESULTS: Among the sample of 1052 participants who completed the survey, 19%
were men and the mean age was 48 years. All 8 SF-36 subscales were significantly
A326 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
